VivoSeq
Respiratory

Chronic Rhinosinusitis With Nasal Polyps

32

Pipeline Programs↗

19

Active Trials↗

24

Companies Involved↗

Chronic Rhinosinusitis With Nasal Polyps is a moderately active landscape with 32 programs across 24 companies. The most active players are Mylan Pharmaceuticals Inc, Amgen, Keymed Biosciences Co.Ltd. 1 therapy is approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

32/100

Mech. Concentration

33/100

Completion Rate

67/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

1 program

Phase 1Amgen logo

Amgen

2 programs

Phase 1K

Keymed Biosciences Co.Ltd

2 programs

Phase 2GSK logo

GSK

1 program

Phase 2G

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

1 program

Phase 2B

Bambusa Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Small molecule

21 of 30 classified programs — the dominant modality here.

30%ALL OTHERSMonoclonal antibody827%Protein / enzyme13%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 95% of 37 pipeline programs.

Analysis

Trial Status

44

clinical trials

Completed14 · 32%
Not yet recruiting6 · 14%
Recruiting6 · 14%
Terminated6 · 14%
Active, not recruiting5 · 11%
Unknown status4 · 9%
Other3 · 7%

Clinical Trials

Trial Activity

44 trials

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Recruiting·Sanofi logoSanofi·Phase 3·NCT06834360·210 enrolled
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Recruiting·Sanofi logoSanofi·Phase 3·NCT06834347·210 enrolled
Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps
Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 3·NCT07132827·280 enrolled
Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Recruiting·—·Phase 4·NCT07187583·135 enrolled
BIFANG: A Multicentre, Single-Arm, Phase 3b Study to Assess Nasal Polyps Score and Symptoms in Chinese Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07520162·230 enrolled
PREDICT: A Prospective, Multicenter Real-World Study to Describe the Clinical Outcome and Quality of Life in Chinese CRSwNP Patients
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07446738·200 enrolled
Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps
Active, not recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT05891483·114 enrolled
A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
Active, not recruiting·—·Phase 4·NCT05942222·220 enrolled
The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT05873803·70 enrolled
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Active, not recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 3·NCT06639295·243 enrolled
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
Active, not recruiting·Sanofi logoSanofi·Phase 2·NCT06454240·79 enrolled
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Not yet recruiting·Sanofi logoSanofi·Phase 3·NCT07484230·20 enrolled
A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps
Not yet recruiting·—·Phase 4·NCT06801353·90 enrolled
A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) .
Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.·N/A·NCT07483268·600 enrolled
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Not yet recruiting·LLongbio Pharma·Phase 2·NCT07313917·150 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)